| Old Articles: <Older 8871-8880 Newer> |
|---|
 |
Chemistry World
June 30, 2014
Phillip Broadwith |
Affymax folds after drug withdrawal Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anemia drug Omontys (peginesatide).   |
Chemistry World
June 30, 2014
Phillip Broadwith |
Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently. |
Chemistry World
June 25, 2014
Derek Lowe |
Too big to innovate? I don't think it's possible to have a discussion about pharmaceutical research productivity without wondering how it might correlate with an organization's size. |
Chemistry World
June 24, 2014
Phillip Broadwith |
Biotech bounced back in 2013, says report Financial services firm EY says in its annual assessment of the global biotechnology sector that the industry is performing strongly, but needs to focus on using its R&D resources more efficiently to 'unlock value'. |
Information Today
June 24, 2014 |
SAGE Rolls Out Digital Healthcare Journal This interdisciplinary, peer-reviewed, open access journal will cover developments in digital health practices, such as genomics research, informatics and technology. |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. |
Information Today
June 17, 2014 |
Wiley Enhances Its Science Solutions Wiley acquired SimBioSys, a scientific software provider of tools used in the drug discovery process. |
Chemistry World
June 16, 2014
Phillip Broadwith |
Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. |
Chemistry World
June 16, 2014
Phillip Broadwith |
Medtronic to buy Covidien for $43bn The deal continues a theme of consolidation within the medical devices sector, with firms looking to broaden their product and service portfolios. |
Chemistry World
June 12, 2014
Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. |
| <Older 8871-8880 Newer> Return to current articles. |
